Co-Authors
                            
                            
                                This is a "connection" page, showing publications co-authored by   Christine Bestvina   and   Jessica Donington.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            0.202
         
        
        
     
 
    
        
        - 
            What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer? Ther Adv Med Oncol. 2023; 15:17588359231198446.
            
            
                Score: 0.054
            
         
        
        - 
            STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2023 01; 7:e2200273.
            
            
                Score: 0.051
            
         
        
        - 
            Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy. J Thorac Oncol. 2022 09; 17(9):1130-1136.
            
            
                Score: 0.050
            
         
        
        - 
            CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
            
            
                Score: 0.047